These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 10404804

  • 1. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2363-8. PubMed ID: 10404804
    [Abstract] [Full Text] [Related]

  • 2. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P, Clemmesen B, Christiansen C.
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [Abstract] [Full Text] [Related]

  • 3. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 5. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 6. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS.
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P.
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [Abstract] [Full Text] [Related]

  • 8. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A, Hannon R, Eastell R.
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [Abstract] [Full Text] [Related]

  • 9. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL, Resnick NM, Parker RA.
    J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
    [Abstract] [Full Text] [Related]

  • 10. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 May; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 12. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
    Pivonello R, Faggiano A, Di Somma C, Klain M, Filippella M, Salvatore M, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
    [Abstract] [Full Text] [Related]

  • 13. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ, Chesnut CH, Mallinak NJ.
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [Abstract] [Full Text] [Related]

  • 14. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.
    Ravn P, Thompson DE, Ross PD, Christiansen C.
    Bone; 2003 Jul; 33(1):150-8. PubMed ID: 12919710
    [Abstract] [Full Text] [Related]

  • 15. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC.
    Osteoporos Int; 2000 Jul; 11(4):295-303. PubMed ID: 10928218
    [Abstract] [Full Text] [Related]

  • 16. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z, Ellakwa H, Desouky B.
    Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
    [Abstract] [Full Text] [Related]

  • 17. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group.
    Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, Christiansen C.
    J Bone Miner Res; 1999 Sep; 14(9):1622-7. PubMed ID: 10469292
    [Abstract] [Full Text] [Related]

  • 18. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, Gorai I.
    J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
    [Abstract] [Full Text] [Related]

  • 19. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.
    Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1492-7. PubMed ID: 10770187
    [Abstract] [Full Text] [Related]

  • 20. Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate.
    Palacios S, Neyro JL, Ferrer J, Villero J, Cañada E, Redondo E, Caloto MT, Nocea G, NTx Study Group.
    Menopause; 2012 Jan; 19(1):67-74. PubMed ID: 21926927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.